

Table 1. Demographics of the whole cohort of “treatment stage III” patients included in the UKW3 study.

Variable		Pathological stage III at time of nephrectomy (Group A)	Pathological stage I and II at time of nephrectomy (Group B)	
		N	N	
Gender	Female	58	17	
	Male	59	15	
Median age at diagnosis in years (range)		3.82 (0.24 to 11.8)	3.26 (0.62 to 10.9)	
Tumour site	Left	55	15	
	Right	62	17	
Tumour operable	Operable	90	0	
	Inoperable	27	32	
Rupture	Yes	42	5*	
	No	72	27	
	Not known	3	0	
Tumour present at margins	Yes	72	3**	
	No	41	25	
	Not known	4	4	
Lymph node Metastasis	Yes	51	0	
	No	54	23	
	Not known	12	9	
Radiotherapy	Flank	89	4	
	Nodes only	2	0	
	Whole abdomen	3	0	
	Unspecified	1	0	
	Not given	22	28	
Pre-operative chemotherapy	Not given	79	0	
	V †	3	0	
	VA †	15	5	
	AVD †	20	26	
	Missing	0	1	
Postoperative chemotherapy	V	1	0	
	VA	6	5	
	AVD	105	24	
	Other	2	0	
	Not recorded / Missing	1	1	
	Not given	2	2	
Overall chemotherapy treatment	VA	4	1	
	AVD	110	29	
	Other	2	0	
	Not given	1	1	
	Missing	0	1	
Relapse site	Did not have relapse	97	28	
	Chest	9	0	
	Abdomen	5	3	
	Distal	1	0	
	Multiple sites	4	1	
	Remaining kidney	1	0	
Status	Alive	101	30	
	Dead	Tumour	12	2
		Other	4	0
Total		117	32	

*Only preoperative suspicion of rupture, not confirmed at final pathology

** Non-viable tumour at resections margins was not considered as stage III in UKW3 trial

† V Vincristine, A Actinomycin D, D doxorubicin

Table 2. Overall treatment received by (A) Group A patients who had an abdominal tumour stage III at the time of nephrectomy and (B) Group B who patients had an abdominal stage I or II tumour at the time of nephrectomy.

A.

Treatment		Radiotherapy		Total
Preoperative	Postoperative	Given	Not given	
V	VA	0	1	1
	AVD	1	1	2
VA	VA	2	0	2
	AVD	11	1	12
	VD+Cyclophosphamide	1	0	1
AVD	V	1	0	1
	VA	1	1	2
	AVD	6	8	14
	Not recorded	1	0	1
	Postsurgical death	0	1	1
	VA+Carboplatin	0	1	1
Immediate nephrectomy	Death during surgery	0	1	1
	VA	1	0	1
	AVD	70	7	77
Total		95	22	117

B.

Treatment		Radiotherapy		Total
Preoperative	Postoperative	Flank	Not given	
AVD	VA	0	4	4
	AVD	2	19	21
	Second line treatment	0	1	1
VA	VA	0	1	1
	AVD	2	1	3
	Not given	0	1	1
Total		4	27	31*

*one patient had missing data on all treatment modalities

Table 3. Distribution of the reasons to be stage III according to (A) whether patients received preoperative chemotherapy or immediate nephrectomy in group A patients and (B) for the 20 relapsing patients and (C) for the 17 patients that received abdominal radiotherapy. The number of reasons for being stage III could be more than one per patient.

A.

Reasons to be stage III	Treatment		Total n=117 (%)
	Immediate nephrectomy n=79 patients (%)	Preoperative chemotherapy n=38 patients (%)	
Tumour rupture	34 (43)	8 (21)	42 (36)
Tumour present at margins	48 (61)	24 (63)	72 (62)
Lymph node metastasis	37 (47)	14 (37)	51 (44)

B.

Reasons to be stage III	Treatment		Total n=20
	Immediate nephrectomy n=10 patients	Preoperative chemotherapy n=10 patients	
Tumour rupture	6	3	9
Tumour present at margins	6	5	11
Lymph node metastasis	5	7	12

C.

Reasons to be stage III	Treatment		Total n=17
	Immediate nephrectomy n=9 patients	Preoperative chemotherapy n=8 patients	
Tumour rupture	6	2	8
Tumour present at margins	6	3	9
Lymph node metastasis	4	6	10

Table 4. Initial treatment of group A patients who experienced a relapse. The number of patients dead (D) is inserted into brackets.

Chemotherapy Treatment		Radiotherapy Treatment		Total n=20 (%)
Preoperative	Postoperative	Flank	Not given	
V	VA	0	1 (D1)	1 (5)
VA	VA	1 (D0)	0	1 (5)
	AVD	4 (D2)	0	4 (20)
AVD	V	1 (D1)	0	1 (5)
	VA	1 (D1)	0	1 (5)
	AVD	1 (D0)	1 (D0)	2 (10)
Not given (immediate nephrectomy)	VA	1 (D1)	0	1 (5)
	AVD	8 (D7)	1 (D0)	9 (45)
Total		17	3	20